Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias
强效、选择性menin-KMT2A抑制剂JNJ-75276617(bleximenib)在KMT2A和NPM1改变的白血病中的临床前疗效
期刊:Blood
影响因子:23.1
doi:10.1182/blood.2023022480
Kwon, Min Chul; Thuring, Jan Willem; Querolle, Olivier; Dai, Xuedong; Verhulst, Tinne; Pande, Vineet; Marien, Ann; Goffin, Dries; Wenge, Daniela V; Yue, Hong; Cutler, Jevon A; Jin, Cyrus; Perner, Florian; Hogeling, Shanna M; Shaffer, Paul L; Jacobs, Frank; Vinken, Petra; Cai, Wei; Keersmaekers, Vikki; Eyassu, Filmon; Bhogal, Balpreet; Verstraeten, Karin; El Ashkar, Sara; Perry, Jennifer A; Jayaguru, Prathiba; Barreyro, Laura; Kuchnio, Anna; Darville, Nicolas; Krosky, Daniel; Urbanietz, Gregor; Verbist, Bie; Edwards, James P; Cowley, Glenn S; Kirkpatrick, Robert; Steele, Ruth; Ferrante, Lucille; Guttke, Christina; Daskalakis, Nikki; Pietsch, E Christine; Wilson, David M; Attar, Ricardo; Elsayed, Yusri; Fischer, Eric S; Schuringa, Jan Jacob; Armstrong, Scott A; Packman, Kathryn; Philippar, Ulrike